BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 27199259)

  • 1. Functional reprogramming of human prostate cancer to promote local attraction of effector CD8(+) T cells.
    Muthuswamy R; Corman JM; Dahl K; Chatta GS; Kalinski P
    Prostate; 2016 Sep; 76(12):1095-105. PubMed ID: 27199259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of IFNα and poly-I:C reprograms bladder cancer microenvironment for enhanced CTL attraction.
    Muthuswamy R; Wang L; Pitteroff J; Gingrich JR; Kalinski P
    J Immunother Cancer; 2015; 3():6. PubMed ID: 25806105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heterodimeric IL-15 delays tumor growth and promotes intratumoral CTL and dendritic cell accumulation by a cytokine network involving XCL1, IFN-γ, CXCL9 and CXCL10.
    Bergamaschi C; Pandit H; Nagy BA; Stellas D; Jensen SM; Bear J; Cam M; Valentin A; Fox BA; Felber BK; Pavlakis GN
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NF-κB hyperactivation in tumor tissues allows tumor-selective reprogramming of the chemokine microenvironment to enhance the recruitment of cytolytic T effector cells.
    Muthuswamy R; Berk E; Junecko BF; Zeh HJ; Zureikat AH; Normolle D; Luong TM; Reinhart TA; Bartlett DL; Kalinski P
    Cancer Res; 2012 Aug; 72(15):3735-43. PubMed ID: 22593190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic infusion of TLR3-ligand and IFN-α in patients with breast cancer reprograms local tumor microenvironments for selective CTL influx.
    Gandhi S; Opyrchal M; Grimm MJ; Slomba RT; Kokolus KM; Witkiewicz A; Attwood K; Groman A; Williams L; Tarquini ML; Wallace PK; Soh KT; Minderman H; Maguire O; O'Connor TL; Early AP; Levine EG; Kalinski P
    J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 37963636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IFN-alpha2a induces IP-10/CXCL10 and MIG/CXCL9 production in monocyte-derived dendritic cells and enhances their capacity to attract and stimulate CD8+ effector T cells.
    Padovan E; Spagnoli GC; Ferrantini M; Heberer M
    J Leukoc Biol; 2002 Apr; 71(4):669-76. PubMed ID: 11927654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Forced LIGHT expression in prostate tumors overcomes Treg mediated immunosuppression and synergizes with a prostate tumor therapeutic vaccine by recruiting effector T lymphocytes.
    Yan L; Da Silva DM; Verma B; Gray A; Brand HE; Skeate JG; Porras TB; Kanodia S; Kast WM
    Prostate; 2015 Feb; 75(3):280-91. PubMed ID: 25399517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TLR9-Targeted STAT3 Silencing Abrogates Immunosuppressive Activity of Myeloid-Derived Suppressor Cells from Prostate Cancer Patients.
    Hossain DM; Pal SK; Moreira D; Duttagupta P; Zhang Q; Won H; Jones J; D'Apuzzo M; Forman S; Kortylewski M
    Clin Cancer Res; 2015 Aug; 21(16):3771-82. PubMed ID: 25967142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells.
    Fujita M; Kohanbash G; Fellows-Mayle W; Hamilton RL; Komohara Y; Decker SA; Ohlfest JR; Okada H
    Cancer Res; 2011 Apr; 71(7):2664-74. PubMed ID: 21324923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peritumoural CCL1 and CCL22 expressing cells in hepatocellular carcinomas shape the tumour immune infiltrate.
    Wiedemann GM; Röhrle N; Makeschin MC; Fesseler J; Endres S; Mayr D; Anz D
    Pathology; 2019 Oct; 51(6):586-592. PubMed ID: 31445808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted knock down of CCL22 and CCL17 by siRNA during DC differentiation and maturation affects the recruitment of T subsets.
    Kang S; Xie J; Ma S; Liao W; Zhang J; Luo R
    Immunobiology; 2010; 215(2):153-62. PubMed ID: 19450895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IL-17 inhibits CXCL9/10-mediated recruitment of CD8
    Chen J; Ye X; Pitmon E; Lu M; Wan J; Jellison ER; Adler AJ; Vella AT; Wang K
    J Immunother Cancer; 2019 Nov; 7(1):324. PubMed ID: 31775909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer.
    Kiniwa Y; Miyahara Y; Wang HY; Peng W; Peng G; Wheeler TM; Thompson TC; Old LJ; Wang RF
    Clin Cancer Res; 2007 Dec; 13(23):6947-58. PubMed ID: 18056169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulatory T cells inhibit CD8(+) T-cell tissue invasion in human skin graft-versus-host reactions.
    Mavin E; Ahmed SS; O'Boyle G; Turner B; Douglass S; Norden J; Collin M; Ali S; Dickinson A; Wang XN
    Transplantation; 2012 Sep; 94(5):456-64. PubMed ID: 22890131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose per Fraction Radiotherapy Induces Both Antitumor Immunity and Immunosuppressive Responses in Prostate Tumors.
    Lin L; Kane N; Kobayashi N; Kono EA; Yamashiro JM; Nickols NG; Reiter RE
    Clin Cancer Res; 2021 Mar; 27(5):1505-1515. PubMed ID: 33219015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NFκB-Activated COX2/PGE
    Ibrahim OM; Basse PH; Jiang W; Guru K; Chatta G; Kalinski P
    Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33809455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of CXCR3 ligand secretion by prostaglandin E2 and cyclooxygenase inhibitors in human breast cancer.
    Bronger H; Kraeft S; Schwarz-Boeger U; Cerny C; Stöckel A; Avril S; Kiechle M; Schmitt M
    Breast Cancer Res; 2012 Feb; 14(1):R30. PubMed ID: 22333315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Helicase-Driven Activation of NFκB-COX2 Pathway Mediates the Immunosuppressive Component of dsRNA-Driven Inflammation in the Human Tumor Microenvironment.
    Theodoraki MN; Yerneni S; Sarkar SN; Orr B; Muthuswamy R; Voyten J; Modugno F; Jiang W; Grimm M; Basse PH; Bartlett DL; Edwards RP; Kalinski P
    Cancer Res; 2018 Aug; 78(15):4292-4302. PubMed ID: 29853604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade.
    House IG; Savas P; Lai J; Chen AXY; Oliver AJ; Teo ZL; Todd KL; Henderson MA; Giuffrida L; Petley EV; Sek K; Mardiana S; Gide TN; Quek C; Scolyer RA; Long GV; Wilmott JS; Loi S; Darcy PK; Beavis PA
    Clin Cancer Res; 2020 Jan; 26(2):487-504. PubMed ID: 31636098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy.
    Peng D; Kryczek I; Nagarsheth N; Zhao L; Wei S; Wang W; Sun Y; Zhao E; Vatan L; Szeliga W; Kotarski J; Tarkowski R; Dou Y; Cho K; Hensley-Alford S; Munkarah A; Liu R; Zou W
    Nature; 2015 Nov; 527(7577):249-53. PubMed ID: 26503055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.